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The Jumonji C (JmjC) family of 2-oxoglutarate (2OG)-dependent oxygenases
have established roles in the regulation of transcription via the catalysis of
demethylation of Ne-methylated lysine residues in histone tails, especially the
N-terminal tail of histoneH3.Most human JmjCN1-methyl lysine demethylases
(KDMs) are complex enzymes, with ‘reader domains’ in addition to their cataly-
tic domains. Recent biochemical evidence has shown that some, but not all, JmjC
KDMs also have Nv-methyl arginyl demethylase (RDM) activity. JmjC KDM
activity has been linked to multiple cancers and some JmjC proteins are thera-
peutic targets. It is, therefore, important to test not only whether compounds
in development inhibit the KDM activity of targeted JmjC demethylases, but
also whether they inhibit other activities of these proteins. Here we report
biochemical studies on the potential dual inhibition of JmjC KDM and RDM
activities using a model JmjC demethylase, KDM4E (JMJD2E). The results
reveal that all of the tested compounds inhibit both the KDM and RDM activi-
ties, raising questions about the in vivo effects of the inhibitors.
This article is part of a discussion meeting issue ‘Frontiers in epigenetic
chemical biology’.1. Background
In organisms varying from bacteria to humans, 2-oxoglutarate (2OG) and Fe(II)-
dependent oxygenases play important roles in the regulation of gene expression
and protein biosynthesis (figure 1) [1–3]. In humans, and other eukaryotes, such
roles include the regulation of transcription via themodification of nucleic acids, his-
tones and transcription factors [4]. The 2OG-dependent hypoxia inducible factor
(HIF) hydroxylases were the first such enzymes shown to have a role in transcrip-
tional regulation. HIF is an a/b-heterodimeric transcription factor that upregulates
the transcription of hundreds of genes, which collectively work to ameliorate the
effects of hypoxia (i.e. by limiting oxygen availability) [5]. Prolyl-hydroxylation of
the HIF-a subunit, which is catalysed by the 2OG-dependent prolyl hydroxylase
domain-containing protein enzymes (PHDs), signals for HIF degradation via the
ubiquitin protease system. There is substantial evidence that PHD catalysis is regu-
lated by oxygen availability in cells and that it acts as a hypoxia-sensingmechanism
for theHIF system. PHD inhibitors are at late stage clinical trials for the treatment of
anaemia, because erythropoietin is a HIF target gene [1].
A second type of 2OG oxygenase-dependent HIF-a modification is cata-
lysed by factor inhibiting HIF (FIH), which also regulates HIF activity.
In humans, and in other higher animals, FIH catalyses the hydroxylation of
an asparaginyl-residue in the C-terminal transactivation domain of HIF-a sub-
units—a post-transcriptional modification that reduces the binding of HIF-a
Figure 1. Proposed catalytic 2OG-dependent mechanism as carried out by ‘hydroxylases’ (e.g. the prolyl hydroxylase domain-containing protein enzymes (PHDs) and factor
inhibiting 2OG-dependent hypoxia inducible factor (FIH)) and demethylases (i.e. the JmjC KDM2-7 human subfamilies). The figure is adapted from [1,2]. Methylated sub-
strates of the JmjC KDMs include mono-, di-, and tri-methylated lysine residues and mono- and di-methylated guanidino nitrogens of arginine resides. In the case of
‘hydroxylases’ (e.g. PHDs and FIH) substrates include 2OG-dependent hypoxia inducible factor (HIF) prolyl- and asparaginyl-residues in HIF-a; FIH also accepts multiple
ankyrin repeat domain proteins. Steps A to C are common to both types of 2OG oxygenases. (A) 2OG binds to the active site Fe(II) in a bidentate manner with consequent
loss of two water molecules. (B) Substrate binding is followed by O2 binding (with displacement of H2O), resulting in, (C), oxidative decarboxylation of 2OG to give succinate,
CO2, and an Fe(IV)¼O intermediate. PHD/FIH active site (hydroxylation) involves formation of a stable alcohol product. JmjC KDM/RDM (demethylation) involves hydroxylation
of the N-methyl group to give a hemiaminal that fragments to produce formaldehyde and the demethylated product.
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2subunits to transcriptional co-activator p300-CBP family of
histone acetyl transferases [6]. The two types of HIF hydroxy-
lases belong to different structural subfamilies of 2OG
oxygenases, with the PHDs belonging to the deacetoxycepha-
losporin C synthase subfamily, which normally have
relatively simple domain architectures [7]. By contrast, FIH
belongs to the normally multidomain JmjC-containing
family of protein [8,9]. Subsequent work identified other sub-
types of JmjC oxygenases [10–14]. FIH is one of the JmjC
‘hydroxylases’ that catalyse the formation of stable alcohol
products [6,15]. Such enzymes include the ribosomal/protein
oxygenases and related 2OG oxygenases catalysing modifi-
cation of the translational machinery [15–17] (figure 1).
N1-methyl lysine demethylases (KDMs) form a subfamily
of JmjC oxygenases that is highly conserved in eukaryotes.
The JmjC KDMs likely evolved from the JmjC hydroxylases
[18] and form the largest known family of KDMs, with the
flavin-dependent lysine specific demethylases (LSDs) being
less ubiquitous [18,19]. The JmjC KDMs catalyse demethyla-
tion of all N1-methylation states of lysine residues (figure 1),
whereas the LSDs only accept the di- and mono-N1-
methylation states [6,14,15]. There are six human subfamilies
of JmjC KDMs that act on histone tails with different N1-
methylation states, histone sequence and ‘adjunct’ protein
selectivities. The JmjC KDMs play central roles in modulatingthe dynamic post-translational methylation states of histones
and can regulate transcription [14,19–21]. The JmjC KDMs
have been linked to multiple diseases, including mutations
that correlate with genetic diseases [22]. Some KDMs are
involved in proliferation and tumour growth, and some are
overexpressed in various cancer types, including breast
cancer and prostate cancer [12,23,24]. As a consequence, certain
JmjC KDMs, including the KDM4 and KDM5 subfamilies, are
being pursued as medicinal chemistry targets.
The correct assignment of function at the (patho)physiolo-
gical level will be important in the rational development of
2OG oxygenase inhibitors. One clinically used compound,
meldonium (used to treatmyocardial infarction), is proposed to
target a human 2OG oxygenase, g-butyrobetaine hydroxylase,
but the precise molecular mode of action of meldonium is
uncertain [25,26]. In the case ofHIF, a combination of biochemi-
cal and physiological studies led to the proposal of an
unexpectedly direct connection between the reaction catalysed
by the PHDs (prolyl-hydroxylation of HIF-a, figure 1) and
hypoxia sensing in animals [27,28], a finding that has stimu-
lated the clinical development of PHD inhibitors for
treatment of anaemia and other hypoxia-related diseases [1].
Subsequent work has revealed complexities in the HIF
system, including reports of a number of non-HIF-a PHD sub-
strates; however, the biological relevance of these substrates
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Figure 2. (a) Matrix assisted laserd desorption/ionization - time of flight mass spectrometry (MALDI-TOF MS) showing demethylation of H3(1-15)K9me2 (top) and
H3(1-15)R2me2a (bottom) as catalysed by KDM4E. A 214 Da shift can be observed after 15 min for both substrates, indicating loss of a methyl group. (b) MALDI-
TOF MS time-course assays showing the fraction of demethylation by KDM4E. Error bars represent s.d. for analytical replicates, n ¼ 2/3. Conditions: 10 mM respect-
ive peptide, 10 mM (NH4)2Fe(SO4)2, 100 mM sodium L-ascorbate, 10 mM 2OG. (c) Correlation for KDM4E KDM versus RDM pIC50 values.
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3and their involvement in the hypoxic response are unclear, and
the key role of the PHDs in HIF-mediated hypoxic response
appears robust [21,29,30]. In contrast, there is good evidence
that FIH not only accepts multiple non-HIF substrates—many
from the ankyrin repeat domains (ARD) structural family—
but it can also catalyse the hydroxylation of residues other
than asparagine, including aspartyl- and histidyl-residues
[21,31]. Like the proposed non-HIF PHD substrates, the biologi-
cal roles of FIH-catalysed ARD hydroxylation are unclear, but
they may serve to regulate the availability of FIH for HIF-a
hydroxylation [21,31]. The promiscuous nature of FIH, in
terms of its substrate and product selectivity, echoes that of
2OG oxygenases and structurally related enzymes involved
in biosynthesis [4,21].
We have been exploring the substrate/product selectivities
of the assigned JmjC KDMs. We have found that some of
them will not only accept a number of unnatural substrate
analogues, but also catalyse Nv-methyl arginine residue
demethylation (RDM), albeit with the RDM activity being
lower than the KDM activity [32,33]. The RDM activity of the
JmjC demethylases has not been validated in cells, in part
due to the paucity of appropriate reagents and antibodies
and, in part, due to the complexity of the chemistry of the
post-translational modifications on the histone H3 tail [32,33].
However, the finding that the JmjC demethylases can catalyse
Nv-methyl arginine residue demethylation raises questions on
the mode of action of the JmjC demethylase inhibitors that are
in development for use as cancer drugs. As with all the HIF
PHD inhibitors that are in clinical trials [1], most (but not all)
of the JmjC KDM inhibitors that have been developed
compete with 2OG and complex to the active site-boundFe(II) (figure 1) [34]. Further, clinically used iron-chelating
compounds such as deferoxamine and ethylenediaminetetra-
acetic acid (EDTA) have potential to inhibit both the KDM
and RDM activity of the JmjC demethylases. Here we report
studies that compare the inhibition of KDM and RDM activity
by a set of reported JmjC demethylase inhibitors with the
model enzyme KDM4E (JMJD2E). The results reveal that the
JmjC KDM inhibitors also inhibit RDM activity of KDM4E,
thus raising questions regarding the mode(s) of action of the
inhibitors in the cellular context.2. Results
To investigate whether JmjC KDM inhibitors also inhibit RDM
activity, we elected to work with KDM4E, a likely pseudo
gene in humans. KDM4E is a relatively simple model JmjC
enzyme,which is reported tohavebothKDMandRDMactivities
andwhich canbe readilyproduced in recombinant form[32]. The
KDM4D, E and F genes are located on a single exon and encode
for only Jumonji N (JmjN) and JmjC domains. By contrast, the
genes for the other human members of the KDM4 family, i.e.
A, B and C, are located on multiple exons and encode for JmjN,
JmjC, PHD-fingers and two TUDOR domains [35,36].
Recombinant KDM4E was produced in Escherichia coli and
purified as reported [37]. We initially optimized assay con-
ditions for comparing KDM/RDM activities using 15mer H3
peptide fragments. These either had a dimethylated lysine at
position nine (H3(1-15)K9me2) or asymmetrically dimethy-
lated arginine at position two (H3(1-15)R2me2a) (figure 2).
Kinetic analysis of KDM4E-catalysed demethylation of
Table 1. pIC50 values for various inhibitors against KDM4E KDM and RDM
activity. Dose– response experiments were performed using the RF-MS-
based assay (n ¼ 3 assay repeats, each assay replicate has n ¼ 3 analytical
replicates). Conditions: 5 mM H3(1-15)K9me2/H3(1-15)R2me2a with
0.25 mM/1 mM KDM4E, respectively, 10 mM (NH4)2Fe(SO4)2, 100 mM
sodium L-ascorbate, 10 mM 2OG; t ¼ 15/25 min for KDM and RDM
activities, respectively, following from analyses shown in electronic
supplementary material, figure S1. Structures of inhibitors are given in
electronic supplementary material, figure S2. s.e.m., standard error of mean.
inhibitor
pIC50+ s.e.m.
inhibition of
H3(1-15)K9me2
demethylation
inhibition of
H3(1-15)R2me2a
demethylation
IOX1 5.65+ 0.03 5.45+ 0.03
2,4-PDCA 6.75+ 0.02 5.96+ 0.03
NOG 5.06+ 0.05 3.91+ 0.10
deferoxaminea 5.62+ 0.03 5.45+ 0.06
EDTAa 5.82+ 6.53 5.95+ 0.06
CPI-455 5.35+ 0.03 5.44+ 0.04
KDOAM25 3.74+ 0.14 3.17+ 0.34
KDM5-C49 5.68+ 0.04 5.04+ 0.05
SD70 5.22+ 0.02 4.65+ 0.04
ML324 5.32+ 0.02 5.31+ 0.04
JIB-04 5.03+ 0.03 4.59+ 0.07
Ni(II)a 6.84+ 0.03 5.80+ 0.06
Co(II)a 7.17+ 0.02 6.19+ 0.04
fumaratea 2.71+ 0.05 2.90+ 0.07
succinatea 3.83+ 0.04 3.15+ 0.05
L-2HGa 4.87+ 0.03 4.14+ 0.05
D-2HGa 4.94+ 0.02 4.40+ 0.05
an ¼ 2 assay repeats.
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4H3(1-15)K9me2 and H3(1-15)R2me2a peptides confirmed that
lysine demethylationwasmore rapid than arginine demethyla-
tion, with specific activities of 13 nmolemin21 mg21 for H3(1-
15)K9me2 and 0.3 nmole min21 mg21 for H3(1-15)R2me2a
demethylation under the employed assay conditions
(figure 2 and electronic supplementary material, S1). These
observations are consistent with the catalytic efficiencies of
these peptides (kcat/KM ¼ 114  1026 s21 mM21 for H3(1-
15)R2me2a and 2167.2  1026 s21 mM21 for H3(1-15)K9me2)
(electronic supplementary material, table S1). We then tested
various classes of reported JmjC KDM inhibitors against both
the KDM and RDM activities, using RapidFire Mass Spec-
trometry (RF-MS), a high throughput-based MS assay. To
ensure robust results, the KDM and RDM assays differed in
their endpoints (15 and 25 min, for KDM and RDM assays,
respectively) and also in the enzyme concentrations used
(0.25 and 1 mM for KDM and RDM assays, respectively). The
2OG concentration was 10 mM, its approximate KM value
(electronic supplementary material, table S1). A panel of
JmjC KDMs inhibitors were then selected (see electronic
supplementary material, figure S2 for compound structures)
and tested under the optimized KDM and RDM assay
conditions.
Initially, we tested the broad-spectrum 2OG oxygenase
inhibitors 5-carboxy-8-hydroxyquinoline (IOX1), 2,4-pyridine-
dicarboxylic acid (2,4-PDCA) and N-oxalylglycine (NOG)
[38–41]. Both RDM and KDM activities were inhibited
approximately equally by IOX1 (pIC50 (RDM) ¼ 5.45+0.03;
pIC50 (KDM) ¼ 5.65+0.03), while 2,4-PDCA (pIC50
(RDM) ¼ 5.96+0.03 and pIC50 (KDM) ¼ 6.75+0.02) and
NOG (pIC50 (RDM) ¼ 3.91+0.10; pIC50 (KDM) ¼ 5.06+
0.05) showed somewhat better inhibition of KDM4E KDM
activity. IOX1, 2,4-PDCA and NOG are 2OG competitive
inhibitors [39–41], whereas IOX1 has been reported to exhibit
mixed-mode inhibition and to cause movement of the active
site metal [38] (table 1, electronic supplementary material,
figure S2). Note that care should be taken in drawing con-
clusions from (small) differences between KDM and RDM
potencies due to the different assay conditions.
We then tested the iron chelators Deferoxamine and EDTA.
Both chelators inhibited both KDM and RDM activities with
similar pIC50 values (deferoxamine: pIC50 (RDM) ¼ 5.45+
0.06 and pIC50 (KDM) ¼ 5.62+0.03, EDTA: pIC50 (RDM) ¼
5.95+0.06, pIC50 (KDM) ¼ 5.82+6.53) (table 1, electronic
supplementary material, figure S2). Nickel(II) and cobalt(II)
ions also inhibited both KDM and RDM activities, likely via
competition with Fe(II) for binding [42].
Certain TCA cycle metabolites inhibit 2OG oxygenases,
including the JmjC KDMs with varying potencies [37,39,
43,44]. In addition, levels of both enantiomers of 2-hydroxyglu-
tarate (L-2HG and D-2HG) can be substantially increased in
some tumours [45]. Succinate, fumarate, L-2HG and D-2HG
were thus tested for inhibition against the KDM and RDM
activities of KDM4E. These metabolites inhibited both KDM
and RDM activities, consistent with prior reports on JmjC
KDM inhibition by 2-hydroxyglutarate [39,44] (table 1, elec-
tronic supplementary material, figure S2). Notably, both
enantiomers of 2-hydroxyglutarate inhibited KDM and RDM
activities with similar efficiency, which accords with their
reported inhibition of the KDM activities of KDM4A and
KDM4C (but not of all 2OG oxygenases) [39].
Inhibitors reported to be selective for specific JmjC KDM
subfamilies were then tested [34]. CPI-455, KDOAM25 andKDM5-C49 are all reported to be selective inhibitors of the
KDM5 subfamily [46–48]. For both CPI-455 and KDM5-C49,
which are reported 2OG competitors [46,48], both KDM and
RDM activities of KDM4E were inhibited (in accordance with
the reported values for KDM4C [46,48]), with pIC50 values
within a close range. As expected from its reported selectivity
profile [47], KDOAM25 proved to be the weakest KDM4E
KDM and RDM inhibitor with pIC50, 4, further supporting
its selectivity towards the KDM5 subfamily. SD70, ML324
and JIB-04 (which unusually to date is identified as a non
2OG competitor [49]) have been reported to be selective inhibi-
tors of the KDM4 subfamily [49–51]. All these compounds
inhibited both KDM and RDM activities and in each case
(except for ML324) with a slightly lower value for the RDM
activity, but all comparable with published IC50 (KDM)
values. ML324 was an equipotent inhibitor for the KDM and
RDM activities (table 1 and electronic supplementary material,
figure S2).
Analysis of KDM and RDM pIC50 values showed a sig-
nificant correlation (Spearman rank correlation r ¼ 0.86,
Pearson’s r ¼ 0.93, p-value, 0.0001), with no significant out-
liers (figure 2). Thus, the overall results reveal that the
analysed compounds inhibit both KDM and RDM KDM4E
r5activities, i.e. are indiscriminate whether the substrate is
H3(1-15)K9me2 or H3(1-15)R2me2a.Glu190
His188
His276
NOG
Ni
Lys9me3
Arg3me2s
Figure 3. View from overlaid X-ray crystal structures of KDM4A complexed
with nickel (substituting for iron), N-oxalylglycine (substituting for 2OG)
and H4(1-15)R3me2s (yellow, PDB ID 2OX0) or H3(7-14)K9me3 (purple,
PDB ID 5FWE) substrates showing similar binding mode for the N-methylated
arginyl- and lysyl-residues at the KDM4A active site.
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The results demonstrate that all of the tested JmjC KDM inhibi-
tors that inhibit via metal chelation (2OG mimetics/generic
metal chelators) inhibit both the KDM and RDM activities of
KDM4E. Overall, the potencies of inhibition were similar for
the KDM and RDM activities, although in some cases, there
were small differences in the apparent potencies. These differ-
ences are likely (at least in part) to be due to the different assay
conditions for the KDM and RDM activities, namely, the
enzyme concentrations used due to KDM4E catalytic efficiency
being 20-fold higher for theH3(1-15)K9me2 peptide than for the
H3(1-15)R2me2a peptide (electronic supplementary material,
figure S1 and table S1). Although KDM4E is a model JmjC
KDM, it is likely that the KDM/RDM dual inhibition will be
observed for most, if not all, JmjC demethylases with RDM
activity. This is because of the overall similarities in the active
sites of the JmjC demethylases and the fact that all tested inhibi-
tors work either by chelation with the active site iron or by
chelating iron in solution [2]. Although the RDM activity of
the JmjC KDMs has not been verified in a cellular context, the
results clearly highlight the need to consider potential activities
beyond KDM catalysis when considering the effects of JmjC
demethylase inhibitors, whether in pharmaceutical form or
when produced endogenously, as is the case as a consequence
of TCA cycle enzyme-associated mutations [37,39,43].
Given the apparent promiscuity of at least some JmjC
demethylases [33], activities beyond KDM/RDM catalysis
should also not be ruled out. In this regard, it is notable that
one other human 2OG oxygenase, JMJD6, has also been
reported to have RDM activity [52]. However, subsequent
work revealed that JMJD6 catalyses hydroxylation of lysyl-C-
5 of mRNA splicing factor proteins and of histones [53,54].
JmjC demethylases may have KDM and RDM activities.
Whether or not JMJD6 is truly a bifunctional RDM/5-
hydroxylase [55], extensive work on microbial 2OG oxyge-
nases involved in secondary metabolite biosynthesis has
revealed that such flexibility in substrate/product selectivity
can and does occur in cells, so the potential for unanticipated
reactivities of human (JmjC) 2OG oxygenases should not be
excluded [3,56]. In the case of human 2OG oxygenases, the ten-
dency to accept multiple substrates is probably best
exemplified in the case of FIH. FIH was initially validated to
catalyse the C-3 asparaginyl-hydroxylation of the C-terminal
transcriptional activator domain of HIF-a [6,15]. Subsequently,
FIHwas shown to catalyse hydroxylation not only of asparagi-
nyl, but also of aspartyl- and histidinyl-residues in cells on
multiple members of the ARD family [31], which have roles
including in, e.g. cell structure and the inflammatory response.
In isolated form, the residue selectivity of FIH has been shown
to be even broader, i.e. where it can accept serine and even
hydrophobic residues [57].
There is thus considerable interest in developing ‘substrate
selective’ 2OG oxygenase inhibitors and, potentially, activa-
tors. Our results suggest that this may be difficult for the
KDM and RDM activities of the JmjC demethylases with
inhibitors that bind to the active site metal. As demonstrated
in X-ray crystal structures (figure 3), both the N-methylated
arginyl- and lysyl-residues (from two different peptides)bind the KDM4A active site with a similar orientation at a
location separate to where N-oxalylglycine, or any other 2OG
competitor, might bind; this further supports the findings
that RDM activity is inhibited in a similar way to KDM inhi-
bition by this class of inhibitors. An alternative approach
would be to develop ‘allosteric’ inhibitors that disrupt binding
of a particular type of substrate (e.g. to generate selective
inhibitors for either KDM or RDM). As a step towards this,
we have beenworking to develop substrate-competitive inhibi-
tors and have recently reported on cyclic peptides that potently
and selectively inhibit JmjC KDM4A, B and C [58].
Alternatively, it is possible that the non-catalytic domains
of the JmjC demethylases could be targeted. The JmjC
demethylases are much more than ‘mere’ catalysts, with most
of them having additional domains to the JmjC/JmjN domains
(with KDM4D, E and F being exceptions). The biological roles
of these domains are still being explored; in some cases, they
can regulate the JmjC KDM activity, as clearly exemplified in
the case of KDM PHD finger protein 8 (PHF8), where its
PHD domain located close to the N-terminus of the JmjC
domain binds to H3K4me3 promoting catalysis at H3K9me2
[59,60]. Thus, at least in some cases, there is potential for the
development of small molecules that bind to the PHD
domain to inhibit H3K9me2 KDM activity. It is possible that
non-catalytic domains of the JmjC demethylases, possibly in
conjunction with interacting proteins and nucleic acids, guide
substrate selectivity both towards specific protein sequences
and the type of reaction catalysed (e.g. KDM versus RDM
activity). To date, little has been reported on the development
of ‘inhibitors’ binding to the non-catalytic domains of the JmjC
demethylases [2,34,61] and although there are challenges, par-
ticularly with respect to biologically relevant assays, this is an
objective of current work in our laboratory.4. Material and methods
(a) Assay reagents
Recombinant KDM4E(1-377)was produced inE. coliBL21(DE3)-R3
containing the pRARE2 plasmid and purified (to greater than 90%
rstb.royalsocietypublishing.org
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6purity by SDS-PAGE analysis) as described [37]. Unless otherwise
specified, reagents were from Sigma-Aldrich. All assays were per-
formed in 50 mM HEPES (pH7.5) buffer. All peptides were
prepared as C-terminal amides. H3(1-15)R2me2a (full sequence:
AR(me2a)TKQTARKSTGGKA-NH2) was synthesized by Peptide
Protein Research, while H3(1-15)K9me2 (full sequence: ARTKQ-
TARK(me2)STGGKA-NH2) was synthesized by GL Biochem.
(b) MALDI-TOF-mass spectrometry (MS)-based assays
Time-course assays: Four different enzyme mixes containing
KDM4E at 2, 1, 0.5 or 0.25 mM were tested with both the H3(1-
15)K9me2 and H3(1-15)R2me2a peptides, and demethylation
activities were monitored over time. KDM4E was allowed to equi-
librate to room temperature for 10 min; the substrate/cofactor
mixturewas then added to initiate the reaction. Final concentrations
in 10 ml reaction volume: 10 mM peptide, 10 mM ammonium
iron(II) sulfate hexahydrate ((NH4)2Fe(SO4)2), 100 mM sodium
L-ascorbate, 10 mM 2-oxoglutaric acid (2OG), as described in [19].
The 2OG concentration used was at approximately the KM value
for KDM4E (electronic supplementarymaterial, table S1). Reactions
were quenched with 1:1 (v/v) aqueous methanol.
On a 96-spot MALDI plate, samples were mixed in a 1:1 ratio
(v/v) with a-cyano-4-hydroxycinnamic acid (CHCA) dissolved in
50% acetonitrile, 0.01% (v/v) aqueous trifluoroacetic acid
(CF3CO2H). The dried spots were analysed using a MALDI-TOF
MS (Micro MX, Waters, UK) machine in the positive ion reflectron
mode; flight tube voltage 12 000 V; reflectron voltage 5200 V.
Spectral analysis was carried out using MassLynx 4.0 (Waters).
The relative peak intensities (RPI) of each methylation state
were used to determine the percentage activity of the enzyme.
All values were normalized using the percentage demethylation
obtained from the first time point.
(c) High-throughput liquid chromatography mass
spectrometry (LC-MS) assays [62]
Assays were performed in 384-well polypropylene
v-bottomed plates (Greiner Bio One). 2,4,PDCA, NOG, Deferox-
amine, EDTA, KDOAM25, ML324, JIB-04, succinic acid disodium
salt hexahydrate (succinate), fumaric acid (fumarate), L-2-hydro-
xyglutarate (HG), D-2HG, nickel (II) sulfate heptahydrate (Ni(II))
and cobalt (II) chloride hexahydrate (Co(II) were from Sigma-
Aldrich, IOX1 was from Stratech Scientific, CPI 455 from Axon
Medchem and KDM5-C49 and SD70 were from Xcess Bio-
sciences. Structures of the inhibitors are defined in electronic
supplementary material, figure S2.
Time-course assays: 1 and 0.25 mM (final concentrations in
50 ml reaction volume) enzyme mixes containing KDM4E were
used with H3(1-15)R2me2a and the H3(1-15)K9me2, respect-
ively; activity was monitored over time. KDM4E was incubated
for 10 min with 1% (v/v) DMSO (dimethylsulfoxide) before
addition of the cofactor/substrate mixture to initiate reaction.
Final concentrations in 50 ml reaction volume: 5 mM respective
peptide, 10 mM (NH4)2Fe(SO4)2, 100 mM sodium L-ascorbate,
10 mM 2OG. The reactions were quenched with 1% (v/v) aqu-
eous formic acid (HCO2H). Assays were carried out with two
analytical repeats.
Inhibition assays: compound dispensing (500 nl) was carried
out using an ECHO 550 Acoustic dispenser (Labcyte). For eachcompound 12 different concentrations were prepared. Compound
concentrations were decreased by a dilution factor of two between
each point. Negative controls (no enzyme activity) and positive
controls (maximum enzyme activity) all contained 500 nl DMSO
without inhibitor.
The KDM4E enzyme mixture (24.5 ml) was transferred into
each well containing 0.5 ml of the compound in DMSO and incu-
bated for 10 min. The reaction was initiated upon addition of
25 ml of the substrate/cofactor mixture. Final concentrations in
a 50 ml reaction volume were: 0.25 mM KDM4E (for KDM
activity) or 1 mM KDM4E (for RDM activity), the compound at
respective concentration, 1% (v/v) aqueous DMSO, 5 mM
respective peptide, 10 mM (NH4)2Fe(SO4)2, 100 mM sodium
L-ascorbate and 10 mM 2OG. The reaction was quenched with
aqueous 1% (v/v) HCO2H after 15 min for KDM activity and
25 min for RDM activity.
The reactions were then transferred to a RapidFire RF360
high-throughput sampling robot connected to an Agilent 6530
Accurate-Mass Quadrupole time-of-flight (Q-TOF) mass spec-
trometer operated in the positive ion mode (Agilent, Wakefield,
MA, USA). Prior to MS analysis, the samples were aspirated
under vacuum for 400 ms then loaded onto a C-18 solid phase
extraction (SPE) cartridge to remove buffer salts from the
samples. This was achieved by washing the cartridge with
0.1% (v/v) HCO2H in water at a flow rate of 1.5 ml min
21 for
4.5 s and followed with an elution step (85% acetonitrile, 15%
deionized water, 0.1% formic acid). The samples were loaded
onto the MS with at a flow rate of 1.25 ml min21 for 4.5 s. The
cartridge was re-equilibrated with water for 500 ms.
For both KDM and RDM assays, the þ5 charge state of the
dimethylated substrate and the mono-methylated product were
used to extract ion chromatogram data. Using RapidFire Integra-
tor software (Agilent, Wakefield, MA, USA), the peak area data
were integrated and produced the relative intensities at each
point. The percentage activity was then calculated. The assays
were repeated two or three times; and, in each case, this was car-
ried out with three analytical repeats.
All data points were combined, producing six or nine dose
response datasets and these were analysed collectively using
GraphPad Prism 5. A non-linear curve with variable slope (the
four-parameter logistic function) was applied to generate the
best-fit LogIC50 values and the LogIC50 standard error mean
(s.e.m.). pIC50+ s.e.m. values were calculated using the
equation, pIC50 ¼ –Log (IC50/M).Data accessibility. The datasets supporting this article have been
uploaded as part of the electronic supplementary material.
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